Our finding suggested that TSG-6 is a promising candidate for alleviating the degree of EBI following SAH, which may expand application in targeting microglial overactivation-mediated inflammation in cerebrovascular diseases. The gene discussed is TNFAIP6; the disease is cerebrovascular disorder.